Breast Cancer Clinical Guidelines
Hormone receptor, HER2, and TNBC-stratified treatment algorithms — biomarker-first, response-adaptive, and integrated with the latest NCCN and ESMO evidence.
Clinical Guideline Sections
Select a subtype to access the full treatment algorithm, trial data, and decision trees.
HR+ Breast Cancer
Hormone receptor–positive, HER2-negative breast cancer — early-stage endocrine therapy, adjuvant CDK4/6 inhibition, and metastatic 1L/2L sequencing including biomarker-driven salvage.
- Early-Stage HR+
- Adjuvant CDK4/6 Inhibitors
- Metastatic HR+ (1L/2L)
- Biomarker-Driven Therapy
HER2+ Breast Cancer
HER2-positive breast cancer — neoadjuvant dual HER2 blockade, pCR-adapted adjuvant strategies, and metastatic sequencing in the DESTINY-Breast09 era.
- Early HER2+ (Neoadjuvant & Adjuvant)
- pCR vs Residual Disease
- Metastatic HER2+ (DESTINY-Breast09 Era)
Triple-Negative Breast Cancer (TNBC)
Triple-negative breast cancer — immunotherapy-integrated neoadjuvant therapy (KEYNOTE-522), residual disease management, and metastatic ADC-era sequencing.
- Early TNBC (KEYNOTE-522)
- TNBC Neoadjuvant & Adjuvant
- Metastatic TNBC (ADC Era)
General Topics & Workup
Breast cancer general principles — initial workup, pathological classification, biomarker interpretation, genetics (BRCA), menopausal status assessment, and bone metastasis management.
- Workup & Imaging
- Pathology & Biomarkers
- Genetics & Menopause
- Bone Disease Management
Clinical reference only. These guidelines are intended to support, not replace, clinical judgment. Treatment decisions should be individualised based on patient-specific factors, local protocols, and multidisciplinary team input. Always apply clinical judgment and consult local institutional guidelines where applicable.